Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 11/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.85 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.85 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.85 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.85 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.85 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.85 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.85 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.85 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.85 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.76 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.68 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3945554 | 0.95 | AKR1C3 (0.85) | APPCYP2C9AKR1C3AKR1C2CYP2C19 | |
| SCHEMBL29926966 | 0.92 | APP (1.00) | APPCYP2C9AKR1C3AKR1C2CYP2C19 | |
| SCHEMBL407631 | 0.92 | APP (1.00) | APPCYP2C9AKR1C3AKR1C2CYP2C19 | |
| SCHEMBL1371930 | 0.87 | APP (0.82) | APPCYP2C9AKR1C3AKR1C2CYP2C19 | |
| SCHEMBL1372754 | 0.86 | AKR1C3 (1.00) | APPCYP2C9AKR1C3AKR1C2CYP2C19 | |
| SCHEMBL2794766 | 0.85 | AKR1C3 (0.64) | APPCYP2C9AKR1C3AKR1C2CYP2C19 | |
| SCHEMBL5448540 | 0.83 | APP (1.00) | APPCYP2C9AKR1C3AKR1C2CYP2C19 | |
| SCHEMBL4990070 | 0.83 | AKR1C3 (0.66) | APPCYP2C9AKR1C3AKR1C2CYP2C19 | |
| SCHEMBL2777333 | 0.82 | APP (1.00) | APPCYP2C9AKR1C3AKR1C2CYP2C19 | |
| SCHEMBL1371366 | 0.82 | APP (0.97) | APPCYP2C9AKR1C3AKR1C2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065567-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND MULTIPLE SCLEROSIS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-05 | — | — | US | claimed |
| US-20130165505-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-27 | — | — | US | claimed |
| US-7662995-B2 | 1-(2-Fluoro-4'-trifluoromethylbiphenyl-4-yl)cyclopropanecarboxylic acid, for example; treatment and/or prevention of Alzheimer's disease; inhibiting the release of A beta 42 peptide thereby being able to modulate gamma-secretase activity without affecting other important metabolic processes | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-02-16 | — | — | US | claimed |
| WO-2006020850-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2006020852-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2006020853-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-9592210-B2 | 1-phenylalkanecarboxylic acid derivatives for the treatment of cognitive impairment | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-03-14 | — | — | US | disclosed |
| WO-2015173133-A1 | FORMULATIONS AND METHODS OF TREATING ALZHEIMER'S DISEASE AND OTHER PROTEINOPATHIES BY COMBINATION THERAPY | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-11-19 | — | — | WO | disclosed |
| US-20150320706-A1 | FORMULATIONS AND METHODS OF TREATING ALZHEIMER'S DISEASE AND OTHER PROTEINOPATHIES BY COMBINATION THERAPY | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-11-12 | — | — | US | disclosed |
| US-20150065567-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND MULTIPLE SCLEROSIS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-05 | — | — | US | disclosed |
| US-20130165505-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-27 | — | — | US | disclosed |
| US-8314268-B2 | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-11-20 | — | — | US | disclosed |
| US-20110288175-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-11-24 | — | — | US | disclosed |
| US-7662995-B2 | 1-(2-Fluoro-4'-trifluoromethylbiphenyl-4-yl)cyclopropanecarboxylic acid, for example; treatment and/or prevention of Alzheimer's disease; inhibiting the release of A beta 42 peptide thereby being able to modulate gamma-secretase activity without affecting other important metabolic processes | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-02-16 | — | — | US | disclosed |
| EP-1594833-B1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CHIESI FARMA SPA (IT) | 2008-09-24 | — | — | EP | disclosed |
| US-20070293538-A1 | Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070060752-A1 | 1-(2-Fluoro-4'-trifluoromethylbiphenyl-4-yl)cyclopropanecarboxylic acid, for example; treatment and/or prevention of Alzheimer's disease; inhibiting the release of A beta 42 peptide thereby being able to modulate gamma-secretase activity without affecting other important metabolic processes | CHIESI FARMACEUTICI S.P.A. (IT) | 2007-03-15 | — | — | US | disclosed |
| WO-2006001877-A2 | COMBINATION TREATMENT FOR NEURODEGENERATIVE DISORDERS COMPRISING R-FLURBIPROFEN | MYRIAD GENETICS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| EP-1594833-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CHIESI FARMACEUTICI S.p.A. (IT) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004074232-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CHIESI FARMACEUTICI S.P.A. (IT) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165505-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | PSEN1, PSEN2, NAT1 | APP 15/4885CYP2C9 1978/4885AKR1C3 505/4885 |
| US-20150320706-A1 | FORMULATIONS AND METHODS OF TREATING ALZHEIMER'S DISEASE AND OTHER PROTEINOPATHIES BY COMBINATION THERAPY | MAPT, GABRA5, MAP1LC3A | APP 6/4885CYP2C9 4477/4885AKR1C3 1077/4885 |
| US-20070060752-A1 | 1-(2-Fluoro-4'-trifluoromethylbiphenyl-4-yl)cyclopropanecarboxylic acid, for example; treatment and/or prevention of Alzheimer's disease; inhibiting the release of A beta 42 peptide thereby being able to modulate gamma-secretase activity without affecting other important metabolic processes | BACE1, APP, BACE2 | APP 2/4885CYP2C9 1801/4885AKR1C3 1458/4885 |
| US-20070293538-A1 | Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders | GRN, NLN, PSEN1 | APP 9/4885CYP2C9 556/4885AKR1C3 504/4885 |
| US-20150065567-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND MULTIPLE SCLEROSIS | PSEN1, APP, PSEN2 | APP 2/4885CYP2C9 3448/4885AKR1C3 740/4885 |
| US-20110288175-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PSEN1, SNCA, PSEN2 | APP 5/4885CYP2C9 3646/4885AKR1C3 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.